Blood GFAP levels provide high specificity for identifying intracerebral hemorrhage in acute stroke patientsBlood tests may help doctors identify types of stroke faster

medRxiv Published September 14, 2026 Study authors: Brassard, C.; Paul, J. F.; ZIEGLER, D.; Chagnon, M.; Bereznyakova, O.; Keezer, M. R.; Gioia, L. C. DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Recognize blood GFAP as a high-specificity rule-in marker for ICH in acute stroke, especially in early time windows.

This meta-analysis evaluates the diagnostic utility of blood GFAP levels in patients with acute stroke. The study focuses on the ability of GFAP to differentiate intracerebral hemorrhage (ICH) from ischemic stroke (AIS) and to identify ICH in undifferentiated suspected stroke cases.

The analysis reports high diagnostic accuracy for identifying ICH. For differentiation between ICH and AIS, the pooled AUC was 0.86 (95% CI: 0.76-0.92) with a specificity of 87.2% (95% CI: 77.0-94.7%). When differentiating ICH from undifferentiated suspected stroke, the pooled AUC was 0.88 (95% CI: 0.79-0.95) and specificity was 90.5% (95% CI: 88.0-96.2%). Accuracy improved in early windows, with an AUC of 0.91 at <6h and 0.96 at <2h from stroke onset.

Several limitations were noted, including limited sensitivity for rule-out testing and insufficient data for small ICH volumes (<10 mL), which often fall below detection limits. There are also knowledge gaps regarding the use of GFAP to assess the extent of ischemic injury in AIS. Clinically, GFAP demonstrates strong rule-in value for ICH due to high specificity, especially in early windows, but it is not recommended as a rule-out test.

How this fits prior evidence

This meta-analysis addresses a gap in identifying biomarkers for differentiating stroke types. While previous evidence noted that remote DWI lesions after ICH signal ischemic injury, the clinical significance of such markers remains uncertain. This finding complements existing knowledge by providing a high-specificity biomarker (GFAP) to rule in ICH, which is a critical distinction given that ICH survivors face an annual 2.1% risk of recurrent ICH and a 2.0% risk of ischemic stroke.

When someone suffers a stroke, every minute counts. Doctors must quickly determine if the stroke is caused by a blood clot or a bleed in the brain. This distinction is vital because the treatments for each type are very different. A new look at blood tests suggests that a protein called GFAP could help make this call more accurately.

Researchers found that testing for GFAP has high specificity, which means it is very good at confirming a brain bleed when it is present. This accuracy is especially high when the test is done very shortly after the stroke begins. The data shows that the test is particularly reliable in the first two hours, making it a strong tool for confirming a bleed in an emergency setting.

While the test is excellent at confirming a bleed, it is not yet perfect at ruling one out because its sensitivity is lower. Additionally, the test may struggle to detect very small bleeds. These findings suggest that while GFAP is a powerful tool for doctors to identify specific types of stroke, it works best when used as part of a broader clinical picture.

What this means for you:

The GFAP protein in blood is highly accurate at confirming brain bleeds during the early stages of a stroke.

Common questions

How accurate is the GFAP test for identifying a brain bleed?

The GFAP test has high specificity, meaning it is very good at confirming a brain bleed. In the first two hours after a stroke, it showed a 96.4% specificity rate. This makes it a strong tool for doctors to confirm a bleed quickly during an emergency.

Can this test be used to rule out a brain bleed?

No, the test is not currently used as a rule-out tool. While it is very good at confirming a bleed, its sensitivity is lower, meaning it might not catch every instance. Doctors should still use other methods to rule out a bleed.

Are there any limitations to using GFAP for stroke diagnosis?

Yes, there are a few limits. The test may not be able to detect very small bleeds, specifically those under 10 mL. There is also still limited information on how well the test can measure the exact extent of injury in cases caused by blood clots.

Study Details

Study typeMeta analysis

Sample sizen = 3

EvidenceLevel 1

PublishedSep 2026

View Original Abstract ↓

Background: Glial fibrillary acidic protein (GFAP) is a promising blood biomarker that can distinguish intracerebral hemorrhage (ICH) from acute ischemic stroke (AIS). We aimed to summarize the existing evidence regarding: 1) the diagnostic accuracy of GFAP to differentiate ICH from AIS, and from undifferentiated suspected stroke, and 2) characterize GFAP's diagnostic accuracy across time strata from stroke onset. As a secondary objective, associations between GFAP and clinical and radiological outcomes were narratively summarized. Methods: Five databases [(MEDLINE/EMBASE/EBM Reviews/CINAHL Complete/Google Scholar] were searched (03/2026) for studies reporting blood GFAP levels in acute stroke. GFAP levels were analyzed according to time from onset to sampling. Risk of bias was assessed using QUADAS-2 for studies reporting diagnostic accuracy data. Forest plots, pooled sensitivities and specificities were calculated. Results: Two reviewers independently screened 6,336 studies; 64 were included for systematic review and 18 for meta-analysis. Risk of bias was low overall among diagnostic studies. For differentiating ICH from AIS, pooled AUC was 0.86 (95% CI: 0.76-0.92), pooled sensitivity 74.4% (95% CI:63.2-84.2%) and pooled specificity 87.2% (95% CI:77.0-94.7%). For ICH versus undifferentiated suspected stroke, pooled AUC was 0.88 (95% CI: 0.79-0.95), pooled sensitivity 75.4% (95% CI: 63.6-83.3%) and pooled specificity 90.5% (95% CI:88.0-96.2%). Diagnostic precision improved in earlier time strata: <6h: AUC 0.91, sensitivity 75.0%, specificity 92.7%; <2h: AUC 0.96, sensitivity 76.7%, specificity 96.4%. GFAP correlated with ICH volume in 11/12 studies, although smaller hematomas (<10 mL) were frequently associated with GFAP values below limits of detection. Few studies (n=3) suggest higher GFAP levels correlate with greater ischemic injury in AIS. Conclusions: As a blood biomarker in acute stroke, GFAP has strong rule-in value (i.e. high specificity) for ICH, which is preserved in earlier time windows. Nevertheless, sensitivity remains limited, restricting its use as a rule-out test, particularly for smaller ICH volumes. Knowledge gaps remain regarding GFAP's potential in assessing ischemic injury extent in AIS.

Blood GFAP levels provide high specificity for identifying intracerebral hemorrhage in acute stroke patientsBlood tests may help doctors identify types of stroke faster

How this fits prior evidence

Common questions

Study Details

Acupuncture and related therapies improve Pittsburgh Sleep Quality Index scores in post-stroke insomnia

Acupuncture therapies show promise for insomnia after a stroke

Clinical research that matters. Delivered to your inbox.

Blood GFAP levels provide high specificity for identifying intracerebral hemorrhage in acute stroke patientsBlood tests may help doctors identify types of stroke faster

How this fits prior evidence

Common questions

More on Stroke

Study Details

Acupuncture and related therapies improve Pittsburgh Sleep Quality Index scores in post-stroke insomnia

Acupuncture therapies show promise for insomnia after a stroke

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties